DIETARY-TREATMENT ELIMINATES SUCCINYLACETONE FROM THE URINE OF A PATIENT WITH TYROSINEMIA TYPE-1

被引:9
|
作者
BAIN, MD
PURKISS, P
JONES, M
BINGHAM, P
STACEY, TE
CHALMERS, RA
机构
[1] CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND
[2] NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND
关键词
Dietary treatment; Succinylacetone; Tyrosinaemia type 1;
D O I
10.1007/BF02034752
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Over an 18-month period serial observations of plasma tyrosine, methionine and urinary tyrosine metabolites were made and compared with urinary succinylacetone excretion in an infant with tyrosinaemia type 1 treated by diet alone. Despite broadly similar profiles there were significant temporal and quantitative differences between each of these metabolic parameters. Only when plasma tyrosine was kept in the low-normal range by strict phenylalanine restriction (10-15 mg phenylalanine/kg body weight) was detectable succinylacetone consistently eliminated from the urine. Urinary succinylacetone is the only measure of metabolite accumulation immediately proximal to the enzyme defect and its routine measurement will allow more effective control of dietary treatment. © 1990 Springer-Verlag.
引用
收藏
页码:637 / 639
页数:3
相关论文
共 50 条
  • [31] Treatment adherence in tyrosinemia type 1 patients
    Gonzalez-Lamuno, Domingo
    Sanchez-Pintos, Paula
    Andrade, Fernando
    Couce, Maria L.
    Aldamiz-Echevarria, Luis
    ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
  • [32] TYPE-1 HEREDITARY TYROSINEMIA - EVIDENCE FOR MOLECULAR HETEROGENEITY AND IDENTIFICATION OF A CAUSAL MUTATION IN A FRENCH-CANADIAN PATIENT
    PHANEUF, D
    LAMBERT, M
    LAFRAMBOISE, R
    MITCHELL, G
    LETTRE, F
    TANGUAY, RM
    JOURNAL OF CLINICAL INVESTIGATION, 1992, 90 (04): : 1185 - 1192
  • [33] THE PKU PARADIGM - THE MIXED RESULTS FROM EARLY DIETARY-TREATMENT
    LEVY, HL
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1986, 31 (02) : 185 - 185
  • [34] CASE OF CHRONIC TYPE-1 THYROXINEMIA - DIETARY TREATMENT AND CLINICAL COURSE
    GABRIELLI, O
    MAIORANA, A
    PARIS, D
    ZANOBINI, R
    RENDA, B
    MONTALI, U
    COPPA, G
    MINERVA PEDIATRICA, 1978, 30 (16) : 1329 - 1334
  • [35] Collaborative medical treatment of a patient suffering from type-1 diabetes mellitus with depression
    Ando, S.
    Ando, M.
    PSYCHOTHERAPY AND PSYCHOSOMATICS, 2015, 84 : 2 - 2
  • [36] CASE OF TYPE-1 TYROSINEMIA, CLINICAL FORM - DIET THERAPY AND CLINICAL EVOLUTION
    GABRIELLI, O
    PARIS, D
    SANI, S
    MARCHINI, G
    ZANOBINI, R
    DAULA, S
    MINERVA PEDIATRICA, 1978, 30 (02) : 191 - 191
  • [37] TYROSINEMIA TYPE-1 - COMPLEX SPLICING DEFECTS AND A MISSENSE MUTATION IN THE FUMARYLACETOACETASE GENE
    ROOTWELT, H
    KRISTENSEN, T
    BERGER, R
    HOIE, K
    KVITTINGEN, EA
    HUMAN GENETICS, 1994, 94 (03) : 235 - 239
  • [38] USE OF UNCOOKED STARCH IN DIETARY-TREATMENT OF PATIENTS FOR TYPE-I GLYCOGENOSIS
    BUHRDEL, P
    BOHME, HJ
    DIDT, L
    ZEITSCHRIFT FUR KLINISCHE MEDIZIN-ZKM, 1990, 45 (11): : 979 - 981
  • [39] 1ST-TRIMESTER PRENATAL-DIAGNOSIS OF TYROSINEMIA TYPE-I BY AMNIOTIC-FLUID SUCCINYLACETONE DETERMINATION
    JAKOBS, C
    STELLAARD, F
    KVITTINGEN, EA
    HENDERSON, M
    LILFORD, R
    PRENATAL DIAGNOSIS, 1990, 10 (02) : 132 - 133
  • [40] Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day
    Kienstra, Nienke S.
    van Reemst, Hannah E.
    van Ginkel, Willem G.
    Daly, Anne
    van Dam, Esther
    MacDonald, Anita
    Burgerhof, Johannes G. M.
    de Blaauw, Pim
    McKiernan, Patrick J.
    Heiner-Fokkema, M. Rebecca
    van Spronsen, Francjan J.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2018, 41 (02) : 181 - 186